Hemostasis Today

March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Paul Breillat: Targeting Inflammatory Cell Death Pathways in VEXAS Syndrome
Mar 4, 2026, 12:45

Paul Breillat: Targeting Inflammatory Cell Death Pathways in VEXAS Syndrome

Paul Breillat, Assistant Clinical Fellow in Internal Medicine and Clinical Immunology at Cochin Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“Excited to share our new publication in Blood on VEXAS syndrome!

In this study, we uncover a pathogenic axis in VEXAS linking UBA1 loss of function and defective ubiquitination to:

  • RIPK1-mediated inflammatory cell death
  • Impaired antimicrobial signaling
  • Defective resolution of inflammation

These findings provide evidence that targeting inflammatory cell death pathways represents a promising therapeutic strategy in VEXAS syndrome.

This work would not have been possible without our extraordinary collaborators David Beck, Samuel Magaziner, Stéphane Camus.

Warm thanks to the Foundation for Medical Research and Fonds IMMUNOV for their invaluable support.

Thanks also to the team at Paris Cardiovascular Research Center – PARCC and to INSERM for providing such a stimulating research environment.

Finally, special thanks to Benjamin Terrier for his mentorship and guidance throughout this project.”

Title: Inflammatory cell death and monocyte dysfunction in VEXAS syndrome

Authors: Paul Breillat, Samuel J Magaziner, Stéphane M. Camus, Léa Dionet, Benjamin De Valence De Minardiere, Pierre Sohier, Amine Majdi, Quentin Delcros, Federica Pallotti, Nadia Rivet, Kevin Chevalier, Margot Poux, Sr., Athena Lam, Pierre-Louis Tharaux, Olivia Lenoir, Abdelrahim Zoued, Olivier Kosmider, David B. Beck, Benjamin Terrier

Read the Full Article on Blood.

Paul Breillat

Stay updated on all scientific advances with Hemostasis Today.